UK MCC CCSG: GMaP Supplement

项目摘要/摘要 Markey癌症中心(MCC)成立于35年前，是一个以大学为基础的机构 英国肯塔基大学癌症中心，这是肯塔基州的旗舰高等教育机构。MCC是 唯一由国家癌症研究所(NCI)指定的肯塔基州癌症中心，该州拥有440万人口，是 美国是全地癌症发病率和死亡率最高的国家，也是MCC的聚集区。超过3.47亿美元 国家、机构和慈善投资，自#年招募MCC主任B.Mark Evers博士(CS)以来 2009年支持了重大的研究和资源扩展，使大量新教师成为可能 招聘、项目开发、临床和共享资源空间的翻新以及最新技术 工具，以及全州的教育和社区外展努力。119个MCC成员抽签 来自英国8所大学的28个系，自2013年以来招聘了28名新教师。癌症相关研究 支付给中冶调查人员的年度总成本超过3870万美元，自2012年以来增加了1030万美元。完毕 在过去的4年里，有9357名受试者参加了介入试验。成员发表了851篇文章 2013年以来以癌症为重点的出版物，其中28%是方案内出版物，16%是方案间出版物，58%是方案内出版物 机构间合作。研究是在4个MCC研究计划内进行的：癌细胞 生物学与信号转导；癌症预防与控制；药物发现、给药与翻译 治疗学；以及基因组不稳定性、表观遗传学和新陈代谢。五个共享资源设施(SRF) 通过为专业知识和高级技术提供强大的基础设施来促进尖端研究 方法：生物样品采购与翻译病理学；生物统计学与生物信息学；癌症 研究信息学；流式细胞术和细胞分选；氧化还原代谢。两个新的SRF(行为 以及基于社区的研究和肿瘤基因组学)正在开发中。重大成就包括： 开发NCI赞助的早期治疗计划，包括一个活跃的分子肿瘤委员会和 精准医学中心；将MCC网络从8个站点扩大到24个站点；建立一个区域 代谢组学中心(U24)；授予2个新的癌症相关中心-生物医学研究中心 癌症和新陈代谢卓越(科布雷)和阿巴拉契亚环境研究中心 科学；以及在全州范围内扩大社区外联/教育倡议。MCC研究热点 关于肯塔基州最严重的癌症负担，重点是陷入困境的阿巴拉契亚肯塔基州地区， 那里的癌症发病率和死亡率超过了整个州。MCC带来了独特的基本、 临床和人口研究的优势，以完成这项任务。这些优势是所有MCC项目不可或缺的 并共同提供强大的能力，将变革性干预研究交付给重要的 服务不足的优先人群，从而为国家通过发现战胜癌症的努力做出贡献 临床翻译、癌症预防和社区外展。

PROJECT SUMMARY/ABSTRACT The Markey Cancer Center (MCC) was established more than 35 years ago as a university-based matrix cancer center at the University of Kentucky (UK), Kentucky's flagship institution of higher education. MCC is the only National Cancer Institute (NCI)-designated Cancer Center in Kentucky, a state of 4.4 million that leads the nation for all-site cancer incidence and mortality and serves as the MCC's catchment area. Over $347M in state, institutional, and philanthropic investment since recruitment of MCC Director Dr. B. Mark Evers (CS) in 2009 have supported significant research and resource expansion, enabling substantial new faculty recruitment, program development, renovation of clinical and shared resource space, and new state-of-the art instrumentation, as well as statewide education and community outreach efforts. The 119 MCC members draw from 28 departments in 8 UK colleges, with 28 new faculty recruited since 2013. Cancer-relevant research funding to MCC investigators exceeds $38.7M in total annual costs, an increase of $10.3M since 2012. Over the last 4 years, 9,357 subjects have been accrued to interventional trials. Members have published 851 cancer-focused publications since 2013, reflecting 28% intra-programmatic, 16% inter-programmatic, and 58% inter-institutional collaborations. Research is conducted within 4 MCC Research Programs: Cancer Cell Biology and Signaling; Cancer Prevention and Control; Drug Discovery, Delivery and Translational Therapeutics; and Genomic Instability, Epigenetics and Metabolism. Five Shared Resource Facilities (SRFs) facilitate cutting-edge research by providing robust infrastructure for specialized expertise and advanced methods: Biospecimen Procurement and Translational Pathology; Biostatistics and Bioinformatics; Cancer Research Informatics; Flow Cytometry and Cell Sorting; and Redox Metabolism. Two new SRFs (Behavioral and Community-Based Research and Oncogenomics) are in development. Significant achievements include: development of an NCI-sponsored early therapeutics program, including an active Molecular Tumor Board and Precision Medicine Center; expansion of the MCC Network from 8 to 24 sites; establishment of a regional Metabolomics Center (U24); award of 2 new cancer-related centers – a Center of Biomedical Research Excellence (COBRE) in Cancer and Metabolism and a Center for Appalachian Research in Environmental Sciences; and expansion of community outreach/education initiatives across the state. MCC research focuses on Kentucky's most serious cancer burdens with emphasis on the “distressed” Appalachian Kentucky region, where cancer incidence and mortality rates surpass those for the entire state. The MCC brings unique basic, clinical, and population research strengths to this mission. These strengths are integral to all MCC programs and collectively provide robust capacity to deliver transformative interventional research to an important underserved priority population, thereby contributing to national efforts to conquer cancer through discovery and clinical translation, cancer prevention, and community outreach.